PRNewswire-PRWebJune 2, 2025
HepQuant Achieves ISO 13485 Certification to Support Scaling of HepQuant DuO™ to Global Clinical Trials
HepQuant, LLC, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is proud to announce ISO 13485 certification as its latest milestone in operational excellence. This internationally recognized certification is a significant achievement that underscores the company's commitment to the highest standards in quality management and regulatory compliance. This milestone enhances HepQuant's abilities to engage in larger, more impactful clinical studies to drive transformative advancements to improve liver health.
May 12, 2025
HepQuant Demonstrates New Advancements in Management of Patients with Acute Liver Failure Dependent on Extracorporeal Liver Cross-Circulation (ELC)
Simultaneous evaluation of Human and Porcine liver functions using 13C-Cholate quantification may aid in future management of patients with acute liver failure who are assisted by ELC systems while awaiting transplant.In The News
April 23, 2025
HepQuant Celebrates Lab Week 2025!
Our amazing lab team is the backbone of our company, powering innovation, precision, and progress every single day. Their dedication to science, quality, and patient impact makes everything we do possible. This week, we recognize and thank our lab professionals for their hard work behind the scenes—advancing liver disease diagnostics and helping improve lives. 🔬 Here’s to the problem solvers, data champions, and science heroes in the lab. We appreciate you today and every day!Events
April 24, 2025 - April 25, 2025Orlando, FL
NAMCP’s Spring Managed Care Forum
HepQuant’s Paige Nardi (VP, Market Access, Billing & Reimbursement) and Kerry Whitaker (Senior Medical Science Liaison) will be attending NAMCP’s Spring Managed Care Forum on April 24–25 at Rosen Creek, Orlando, FL. Stop by Booth 216 to meet with them!
Amsterdam, the Netherlands | May 7 - 10, 2025
EASL Congress 2025
HepQuant’s own Dr. Gregory T. Everson, CEO will present two posters at EASL Congress 2025 in Amsterdam, the Netherlands May 7 – 10. Top Poster #507 “Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent” and poster #355 “The HepQuant…
San Diego, CA | May 3 -6, 2025
DDW 2025
Dr. Gregory T. Everson, CEO and founder of HepQuant, will discuss “Simultaneous Quantification of Native Human Liver and Porcine Liver Function in an Extracorporeal Circuit Using IV 13C-Cholate.” at the upcoming DDW 2025 Late-Breaking Plenary session on May 3, 2025. Please join him in Room 25 from 2:00 to 3:00 pm…